Global Antifungal Drug Market In the Rise and To Register a Revenue of USD 91.81 Billion in 2032

The worldwide antifungal medications market was worth USD 13.81 billion in 2021 and is predicted to grow at a 3.6% CAGR over the forecast period. Increasing high-value investments in the healthcare sector, as well as R&D endeavors by big corporations, is a key element driving market revenue growth. Furthermore, the rising frequency of various fungal skin illnesses combined with increased awareness about fungal disease for early detection and prevention, is propelling market revenue growth.

Majority of life-threating fungal infections inflicts individuals with altered immune function, such as HIV/AIDS, cancer chemotherapy, and hematology, among others. Rising incidence of invasive fungal infections along with immunodeficiency diseases is another major factor driving demand for antifungal drugs In addition, ease of application of antifungal treatments in the form of oral tablets, topical cream/ointment, and IV drips, as well as their availability as over-the-counter medications, is a key factor increasing demand for antifungal drugs by the healthcare sector, as per Emergen Research.

Furthermore, increased R&D for new formulated drugs for the treatment of fungal infections is adding to market expansion. MSN Labs announced Posaconazole under the trademark PosaOne on May 21, 2021, for the treatment of fatal black fungus in the form of injections and delayed-release tablets. PosaOne, a triazole antifungal medicine approved for the treatment of mucormycosis, is now available in 100mg delayed-release tablets and 300mg injections.